WAM
SMMT icon

Worth Asset Management’s Summit Therapeutics SMMT Stock Holding History

Worth Asset Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-10,956
Closed -$28.6K – 142
2023
Q4 		$28.6K Hold
10,956
– – 0.02% 109
2023
Q3 		$20.5K Hold
10,956
– – 0.02% 93
2023
Q2 		$27.5K Buy
10,956
+1,500
+16% +$2.74K 0.02% 217
2023
Q1 		$16.5K Buy
9,456
+6,456
+215% +$17.6K 0.01% 279
2022
Q4 		$12.8K Hold
3,000
– – 0.01% 287
2022
Q3 		$4K Buy
3,000
+2,000
+200% +$2.26K ﹤0.01% 370
2022
Q2 		$1K Hold
1,000
– – ﹤0.01% 510
2022
Q1 		$1K Buy
+1,000
New +$2.52K ﹤0.01% 517

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Worth Asset Management's SMMT Position: Q1 2024 in Review

Worth Asset Management sold out of Summit Therapeutics (SMMT) in Q1 2024, closing a stake of 10,956 shares — an estimated $28.6K sold.

Worth Asset Management first reported a position in SMMT in Q1 2022 and held it in 8 quarters. The position peaked at $28.6K in Q4 2023. 105 funds tracked by Wall St. Rank hold SMMT as of Q1 2024.

  • Worth Asset Management reported no remaining Summit Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Worth Asset Management sold 10,956 Summit Therapeutics shares in Q1 2024, an estimated $28.6K.
  • Worth Asset Management first reported a position in Summit Therapeutics in Q1 2022 and held it in 8 quarters.
  • Worth Asset Management's Summit Therapeutics position peaked at $28.6K in Q4 2023.
  • 105 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2024.

Based on Worth Asset Management's 13F filing for Q1 2024, filed 12 Apr 2024.